{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:05:22Z","timestamp":1790460322508,"version":"4.1.0"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vera Therapeutics and Merck Serono"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Idiopathic inflammatory myopathies (IIMs) are a rare and heterogeneous group of chronic autoimmune disorders. Up to 40% of IIM patients have long-term sequelae and significant functional disability. Its management can be challenging and new therapies are badly needed. The small number of cases with diverse presentations and different diagnostic criteria significantly affect clinical trial results. Only IVIG has been internationally approved for IIM patients. Most clinical trials of new biologic therapies have failed to meet their primary endpoints in IIM, with only one biologic drug recommended for refractory IIM treatment (rituximab), although not approved. We review several new emerging biologic drugs, including B cell depletion therapies, abatacept, Janus kinase inhibitors, and aldesleukin. Encouragingly, some phase II randomized controlled trials have evaluated the efficacy and safety of new biologics in IIM, demonstrating an improvement in clinical and laboratory measures.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae096","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:22:26Z","timestamp":1707279746000},"page":"2938-2947","source":"Crossref","is-referenced-by-count":9,"title":["Where are we now in biologic drugs for myositis?"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-1050","authenticated-orcid":false,"given":"Ana","family":"Neves","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o , Oporto,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6679-2762","authenticated-orcid":false,"given":"Lu\u00edsa","family":"Viveiros","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio , Oporto,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Venturelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Universit\u00e0 degli Studi di Ferrara, Azienda Ospedaliero-Universitaria S. Anna , Cona,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David A","family":"Isenberg","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Department of Medicine, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024110419220028500_keae096-B1","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2024110419220028500_keae096-B2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2024110419220028500_keae096-B3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","article-title":"Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases","volume":"83","author":"Dank\u00f3","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"2024110419220028500_keae096-B6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B7","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024110419220028500_keae096-B8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B9","author":"NHS England","year":"2016"},{"key":"2024110419220028500_keae096-B10","author":"NHS England","year":"2021"},{"key":"2024110419220028500_keae096-B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.23248","article-title":"The provisional Paediatric Rheumatology International Trials Organisation\/American College of Rheumatology\/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study","volume":"59","author":"Ruperto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B13","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative [published correction appears in Arthritis Rheumatol. 2018 Mar;70(3):467]","volume":"69","author":"Rider","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024110419220028500_keae096-B15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"2024110419220028500_keae096-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"2024110419220028500_keae096-B17","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations","volume":"34(Suppl 1)","author":"Dalakas","year":"2014","journal-title":"J Clin Immunol"},{"key":"2024110419220028500_keae096-B18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"2024110419220028500_keae096-B19","doi-asserted-by":"crossref","first-page":"102997","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2024110419220028500_keae096-B20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2024110419220028500_keae096-B21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S157085","article-title":"Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis","volume":"14","author":"Li","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2024110419220028500_keae096-B22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2022-328881","article-title":"IVIg-exposure and thromboembolic event risk: findings from the UK Biobank","volume":"93","author":"Kapoor","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024110419220028500_keae096-B23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13(Suppl 2)","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"2024110419220028500_keae096-B24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","article-title":"Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies","volume":"58","author":"de Souza","year":"2018","journal-title":"Adv Rheumatol"},{"key":"2024110419220028500_keae096-B26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024110419220028500_keae096-B28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2024110419220028500_keae096-B29","doi-asserted-by":"crossref","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"2024110419220028500_keae096-B30","doi-asserted-by":"crossref","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"2024110419220028500_keae096-B31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024110419220028500_keae096-B32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","article-title":"A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment","volume":"27","author":"Koichi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2024110419220028500_keae096-B33","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2024110419220028500_keae096-B34","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"2024110419220028500_keae096-B35","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1093\/rheumatology\/kead010","article-title":"Rituximab in myositis: where are we now? A survey of current usage","volume":"62","author":"Oliveira","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keac438","article-title":"Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies","volume":"62","author":"Janardana","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B37","doi-asserted-by":"crossref","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis\/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"key":"2024110419220028500_keae096-B38","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1093\/rheumatology\/keac398","article-title":"Adverse events of treatment with rituximab in patients with myositis","volume":"62","author":"Gilaberte","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2024110419220028500_keae096-B40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest"},{"key":"2024110419220028500_keae096-B41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis","volume":"20","author":"Kry\u0161t\u016ffkov\u00e1","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024110419220028500_keae096-B42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/mus.21739","article-title":"Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles","volume":"42","author":"Salajegheh","year":"2010","journal-title":"Muscle Nerve"},{"key":"2024110419220028500_keae096-B43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkov\u00e1","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B44","author":"GlaxoSmithKline"},{"key":"2024110419220028500_keae096-B45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","author":"Marder","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol"},{"key":"2024110419220028500_keae096-B47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B48","doi-asserted-by":"crossref","first-page":"e12732","DOI":"10.1111\/sji.12732","article-title":"Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis","volume":"89","author":"Tang","year":"2019","journal-title":"Scand J Immunol"},{"key":"2024110419220028500_keae096-B49","article-title":"Randomized placebo-controlled trial to evaluate efficacy and safety of subcutaneous abatacept in adults with active idiopathic inflammatory myopathy: results of the 24-week double-blind and 28-week open-label periods [abstract]","author":"Aggarwal","journal-title":"Arthritis Rheumatol 2022;74(suppl 9). https:\/\/acrabstracts.org\/abstract\/randomized-placebo-controlled-trial-to-evaluate-efficacy-and-safety-of-subcutaneous-abatacept-in-adults-with-active-idiopathic-inflammatory-myopathy-results-of-the-24-week-double-blind-and-28-week-op\/ (26 February 2024, date last accessed)."},{"key":"2024110419220028500_keae096-B50","doi-asserted-by":"crossref","first-page":"i109","DOI":"10.1136\/ard.59.suppl_1.i109","article-title":"Advances in interleukin 2 receptor targeted treatment","volume":"59(Suppl 1)","author":"Morris","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B52","first-page":"474","article-title":"CD25 blockade for refractory polymyositis","volume":"31","author":"Pipitone","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2024110419220028500_keae096-B53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1756285613504021","article-title":"The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis","volume":"7","author":"Milo","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"2024110419220028500_keae096-B54","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"2024110419220028500_keae096-B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"2024110419220028500_keae096-B56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","article-title":"Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Neurol"},{"key":"2024110419220028500_keae096-B57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"2024110419220028500_keae096-B58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/rheumatology\/keu484","article-title":"Long-term efficacy of alemtuzumab in polymyositis","volume":"54","author":"Ruck","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B59","first-page":"001368","article-title":"Inclusion body myositis treated with alemtuzumab","volume":"6","author":"S\u00e1","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"2024110419220028500_keae096-B60","first-page":"2080","article-title":"Alemtuzumab (Campath-1H) for treatment of refractory polymyositis","volume":"35","author":"Thompson","year":"2008","journal-title":"J Rheumatol"},{"key":"2024110419220028500_keae096-B61","article-title":"Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in Inclusion Body Myositis (IBM) [abstract]","author":"Goel"},{"key":"2024110419220028500_keae096-B62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/ar3150","article-title":"Type I IFN and TNF\u03b1 cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance","volume":"12","author":"Cantaert","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024110419220028500_keae096-B63","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12(Suppl 1)","author":"Greenberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024110419220028500_keae096-B64","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B65","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.nmd.2020.09.026","article-title":"Adalimumab and myositis: a case report and review of the French and international Pharmacovigilance Databases","volume":"30","author":"Gaboriau","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2024110419220028500_keae096-B66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Muscle Study Group","year":"2011","journal-title":"Ann Neurol"},{"key":"2024110419220028500_keae096-B67","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"2024110419220028500_keae096-B68","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2024110419220028500_keae096-B69","doi-asserted-by":"crossref","first-page":"179180","DOI":"10.1155\/2014\/179180","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"2014","author":"Brunasso","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"2024110419220028500_keae096-B70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B71","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"2024110419220028500_keae096-B72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/art.41096","article-title":"Circulating interferon-\u03b1 measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity: comment on the article by Mathian et al","volume":"72","author":"Melki","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024110419220028500_keae096-B73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B74","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"2024110419220028500_keae096-B75","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B77","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024110419220028500_keae096-B78","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","article-title":"Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis","volume":"42","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2024110419220028500_keae096-B79","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan","year":"2022","journal-title":"J Rheumatol"},{"key":"2024110419220028500_keae096-B80","first-page":"575","article-title":"POS0607 brepocitinib prevents type-I interferon induced damage in cultured myocytes and endothelial cells indicating a potential role in the treatment of dermatomyositis","volume":"82(Suppl 1)","author":"Vencovsk\u00fd","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B81","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024110419220028500_keae096-B82","doi-asserted-by":"crossref","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"},{"key":"2024110419220028500_keae096-B83","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2024110419220028500_keae096-B85","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B86","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2024110419220028500_keae096-B87","doi-asserted-by":"crossref","first-page":"635654","DOI":"10.3389\/fphar.2021.635654","article-title":"The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024110419220028500_keae096-B88","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","article-title":"The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome","volume":"55","author":"Murphy","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jbspin.2015.03.016","article-title":"Antisynthetase syndrome treated with tocilizumab","volume":"83","author":"Beaumel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2024110419220028500_keae096-B90","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0000000000000430","article-title":"A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab","volume":"23","author":"Montoya","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2024110419220028500_keae096-B92","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/kez020","article-title":"Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome","volume":"58","author":"Pinal-Fernandez","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B93","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.22388","article-title":"Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies","volume":"56","author":"Grundtman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024110419220028500_keae096-B94","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3899\/jrheum.220213","article-title":"Anakinra for the treatment of antisynthetase syndrome: a monocentric case series and a systematic literature review","volume":"50","author":"Campochiaro","year":"2023","journal-title":"J Rheumatol"},{"key":"2024110419220028500_keae096-B96","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1212\/NXI.0000000000000581","article-title":"Trial of canakinumab, an IL-1\u03b2 receptor antagonist, in patients with inclusion body myositis","volume":"6","author":"Kosmidis","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024110419220028500_keae096-B97","doi-asserted-by":"crossref","first-page":"105912","DOI":"10.1016\/j.intimp.2019.105912","article-title":"Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis","volume":"77","author":"Feng","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2024110419220028500_keae096-B98","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40744-021-00301-3","article-title":"Treatment of active idiopathic inflammatory myopathies by low-dose interleukin-2: a prospective cohort pilot study","volume":"8","author":"Miao","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024110419220028500_keae096-B99","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.1002\/art.10125","article-title":"A pilot study of eculizumab in patients with dermatomyositis","volume":"46","author":"Kazuki","year":"2002","journal-title":"Arthritis Res"},{"key":"2024110419220028500_keae096-B100","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"2024110419220028500_keae096-B101","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"2024110419220028500_keae096-B102","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"2024110419220028500_keae096-B103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"2024110419220028500_keae096-B104","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"2024110419220028500_keae096-B105","doi-asserted-by":"crossref","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","article-title":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis","volume":"95","author":"Sivakumar","year":"2020","journal-title":"Neurology"},{"key":"2024110419220028500_keae096-B106","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1212\/WNL.0000000000203877","article-title":"Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis (P1-5.018)","volume":"100","author":"P\u00e9rez-Ruixo","year":"2023","journal-title":"Neurology"},{"key":"2024110419220028500_keae096-B107","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419220028500_keae096-B108","article-title":"KZR-616, a first-in-class selective inhibitor of the immunoproteasome, ameliorates polymyositis in a murine model [abstract]","author":"Del Rio Oliva"},{"key":"2024110419220028500_keae096-B109","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bmt.1703048","article-title":"Dermatomyositis and sarcoid-like reaction associated with multiple myeloma treated effectively by high-dose chemotherapy and autologous peripheral blood stem cell transplantation","volume":"27","author":"Chakraverty","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2024110419220028500_keae096-B110","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10067-005-1109-6","article-title":"Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis","volume":"24","author":"Oryoji","year":"2005","journal-title":"Clin Rheumatol"},{"key":"2024110419220028500_keae096-B111","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2141.2000.02191.x","article-title":"Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation","volume":"110","author":"Baron","year":"2000","journal-title":"Br J Haematol"},{"key":"2024110419220028500_keae096-B112","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2008.094755","article-title":"Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation","volume":"68","author":"Henes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024110419220028500_keae096-B113","doi-asserted-by":"crossref","first-page":"e0006","DOI":"10.5041\/RMMJ.10493","article-title":"The emerging role of mitochondrial dysfunction in the pathogenesis of idiopathic inflammatory myopathies","volume":"14","author":"Gonzalez-Chapa","year":"2023","journal-title":"Rambam Maimonides Med J"},{"key":"2024110419220028500_keae096-B114","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"2024110419220028500_keae096-B115","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"2024110419220028500_keae096-B116","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2024110419220028500_keae096-B117","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"2024110419220028500_keae096-B118","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/ene.15231","article-title":"Sirolimus leads to rapid and sustained clinical improvement of motor deficits in a patient with inclusion body myositis","volume":"29","author":"Pawlitzki","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024110419220028500_keae096-B119","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024110419220028500_keae096-B120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae096\/56817146\/keae096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/2938\/60415518\/keae096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/2938\/60415518\/keae096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:22:30Z","timestamp":1730748150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/11\/2938\/7602153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":120,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae096","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,2,6]]}}}